Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
183 results about "Oxindole" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Oxindole (2-indolone) is an aromatic heterocyclic organic compound. It has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring. Oxindole is a modified indoline with a substituted carbonyl at the second position of the 5-member indoline ring.
Nitric oxide releasing oxindole prodrugs for anagesic, Anti-inflammatory and disease-modifying use
Nitric oxide releasing oxindole prodrugs are described which are useful in methods of treating or preventing pain, inflammation, fever, or gastrointestinal lesions in a patient in need of such treatment, or of modifying an inflammatory disease or condition by favorably affecting the outcome thereof in said patient, wherein there is administered to said patient a therapeutically effective amount of a compound of Formula (I): and pharmaceutically acceptable salts thereof. In preferred embodiments, X is a covalent bond; RA and RB are both hydrogen; n is the integer 4; Y is -O-; Z is -NO2; RC is a member selected from the group consisting essentially of 5-Cl and 5-F; RD is a member selected from the group consisting essentially of 6-Cl and 6-F; and RE is a member selected from the group consisting essentially of benzyl, 2-furyl, 2-thienyl, 5-chloro-2-thienyl and 5-trifluoromethyl-2-thienyl.
Owner:PFIZER INC +1
Use of spiro-oxindole compounds as therapeutic agents
ActiveUS8466188B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderMedicineEnantiomer
Owner:XENON PHARMACEUTICALS INC
Thio-oxindole derivatives
This invention relates to methods of co-administering compounds of formula 1 which are agonists of the progesterone receptor which have the general structure: wherein: R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, with estrogen, an estrone, or an estrogen receptor agonist for contraception, hormone replacement therapy, or treating progesterone-related carcinomas and adenocarcinomas.
Owner:WYETH LLC
Oxindole compounds and their uses as therapeutic agents
InactiveUS20070105820A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderOxindoleDisease cause
Owner:XENON PHARMACEUTICALS INC
Use
The present invention relates to a new use of oxindole derivatives of formula I, as a free base or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the prevention and / or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3. Formula (I) wherein R1, R2, R3, ring Z, m and n are as defined as in claim 1. The present invention further relates to a method of prevention and / or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3, as well as a pharmaceutical composition for said use.
Owner:ASTRAZENECA AB
Process for preparing 2-oxindoles and N-hydroxy-2-oxindoles
InactiveUS6469181B1Avoid wastingImprove economyCarboxylic acid nitrile preparationOrganic compound preparationReaction intermediateCarboxylic salt
The present invention provides a processes, having practical utility, for preparing 2-oxindoles, N-hydroxy-2-oxindoles, or mixtures thereof comprising: catalytically hydrogenating a 2-nitroarylmalonate diester to produce a 2-(N-hydroxyamino)arylmalonate diester, a 2-aminoarylmalonate diester, or mixtures thereof as a first reaction intermediate; cyclizing, by intramolecular aminolysis of one ester group, the first reaction intermediate to produce a N-hydroxy-2-oxindole-3-carboxylate ester, 2-oxindole-3-carboxylate ester, or mixtures thereof as a second reaction intermediate; and hydrolyzing and decarboxylating the remaining ester group of the second reaction intermediate to produce the N-hydroxy-2-oxindole, the 2-oxindole, or mixtures thereof, wherein the cyclization reaction and the hydrolysis and decarboxylation reaction are conducted in situ with the catalytic hydrogenation reaction without isolation of said reaction intermediates.
Owner:CATALYTICA PHARMA
Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
InactiveUS20060247441A1Readily apparentBiocideCarboxylic acid nitrile preparationThio-Benzothiophene
Methods for preparing oxindole and thio-oxindole compounds are provided, which compounds are useful as precursors to useful pharmaceutical compounds. Specifically provided are methods for preparing 5-pyrrole-3,3-oxindole compounds and 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile. Also provided are methods for preparing iminobenzo[b]thiophene and benzo[b]thiophenone compounds.
Owner:WYETH LLC
Spiro-oxindole compounds and their uses as therapeutic agents
ActiveUS7700641B2Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseMedicine
Owner:XENON PHARMACEUTICALS INC
Thio-oxindole derivatives
This invention relates to compounds which are agonists of the progesterone receptor which have the general structure: wherein:R1, R2, R3, R4, R5 and Q1 are as defined herein, or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.
Owner:WYETH LLC
New Substituted Oxindole Derivative 352
The present invention relates to a new compound of formula (I)6-(5-cyano-2-hydroxy-1H-indol-3-yl)pyridine-3-carboxylic acid or a pharmaceutically acceptable salt thereof, in an essentially pure and isolated form, pharmaceutical formulations containing said compounds, to the use of said active compounds in therapy, and methods of prevention and / or treatment of conditions associated with glycogen synthase kinase-3 related disorders, comprising administering to a mammal, including human in need of such prevention and / or treatment, a therapeutically effective amount of said compound, as well as a process for preparing said compound.
Owner:ASTRAZENECA AB
Spiro-oxindole mdm2 antagonists
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN
Spiro-oxindole mdm2 antagonists
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +1
Oxindoles with anti-HIV activity
The present invention relates to inhibition of viruses, e.g., HIV using oxindoles and compounds related to oxindoles. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
Owner:THE SCRIPPS RES INST +1
Spiro-oxindole-derivatives as sodium channel blockers
InactiveUS20110269788A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerChannel blocker
This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole MDM2 antagonists
Owner:RGT UNIV OF MICHIGAN +1
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions.
Owner:PACIRA THERAPEUTICS INC
3-3-di-substituted-oxindoles as inhibitors of translation initiation
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
InactiveUS20110294842A9Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00001.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00002.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/1ebd3ab6-9e2b-45ac-b2ff-acba37a43ecd/US20110294842A9-20111201-C00003.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
Owner:XENON PHARMACEUTICALS INC
Methods of treating skin disorders using thio-oxindole derivatives
The present invention provides methods of treating skin disorders includes delivering to a mammal a composition containing a compound of formula I, or tautomers thereof, in a regimen, wherein formula I is:and wherein R1–R5 and Q1 are defined as described herein. Specifically, methods for treating acne, hirsutism, and a composition for conditioning the skin are described.
Owner:WYETH LLC
Spiro-oxindole compounds and their use as therapeutic agents
InactiveUS20100099728A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
Owner:XENON PHARMACEUTICALS INC
Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
InactiveUS20100160291A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.
Owner:XENON PHARMACEUTICALS INC
Spiro-oxindole MDM2 antagonists
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +2
Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
InactiveUS20100160362A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderDiseaseEnantiomer
This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and / or prevention of sodium channel-mediated diseases or conditions, such as pain.
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00001.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00002.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
![Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain](https://images-eureka.patsnap.com/patent_img/35d4f33d-716a-4dd1-86e5-d03d38ec2191/US20100160362A1-20100624-C00003.png "Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain")
Owner:XENON PHARMACEUTICALS INC
Method for preparing tricarbazole materials from aryl oxindole in one step
The invention provides a method for preparing tricarbazole materials from aryl oxindole in one step. The method utilizes aryl oxindole as a raw material, and directly obtains tricarbazole compounds through one-step synthesis under the condition that phosphorus oxychloride is used as a dehydrating agent. The method solves the problems that methods for synthesizing tricarbazole compounds in the prior art have long steps, and there is only one single way for introducing substituents into tricarbazole compounds. The obtained compound can be hopefully used for organic light emitting diodes.
Owner:NANJING UNIV OF TECH
Use of spiro-oxindole compounds as therapeutic agents
ActiveUS20100173967A1Improve effectivenessDecrease the adverse eventsBiocideNervous disorderEnantiomerMedicine
This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R1, R2a, R2b, R2c, R2d, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and / or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer.
Owner:XENON PHARMACEUTICALS INC
Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
ActiveUS20130274483A1Useful in treatmentNervous disorderOrganic chemistryDiseaseEnantioselective synthesis
Owner:PACIRA THERAPEUTICS INC
Spiro-oxindole mdm2 antagonists
InactiveUS20120122947A1Improve anti-tumor activityGreat clinical benefitBiocideOrganic chemistryDiseaseMedicine
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
Owner:RGT UNIV OF MICHIGAN +2
Spiro-oxindole MDM2 antagonists
Owner:RGT UNIV OF MICHIGAN
Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and / or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and / or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).
Owner:MERCK SERONO SA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com